By continuing to browse our site you agree to our use of cookies, revised Privacy Policy and Terms of Use. You can change your cookie settings through your browser.
I agree
Search Trends
CHOOSE YOUR LANGUAGE
- Albanian Shqip
- Arabic العربية
- Belarusian Беларуская
- Bengali বাংলা
- Bulgarian Български
- Cambodian ខ្មែរ
- Croatian Hrvatski
- Czech Český
- English English
- Esperanto Esperanto
- Filipino Filipino
- French Français
- German Deutsch
- Greek Ελληνικά
- Hausa Hausa
- Hebrew עברית
- Hungarian Magyar
- Hindi हिन्दी
- Indonesian Bahasa Indonesia
- Italian Italiano
- Japanese 日本語
- Korean 한국어
- Lao ລາວ
- Malay Bahasa Melayu
- Mongolian Монгол
- Myanmar မြန်မာဘာသာ
- Nepali नेपाली
- Persian فارسی
- Polish Polski
- Portuguese Português
- Pashto پښتو
- Romanian Română
- Russian Русский
- Serbian Српски
- Sinhalese සිංහල
- Spanish Español
- Swahili Kiswahili
- Tamil தமிழ்
- Thai ไทย
- Turkish Türkçe
- Ukrainian Українська
- Urdu اردو
- Vietnamese Tiếng Việt
Copyright © 2024 CGTN.
京ICP备20000184号
CHOOSE YOUR LANGUAGE
- Albanian Shqip
- Arabic العربية
- Belarusian Беларуская
- Bengali বাংলা
- Bulgarian Български
- Cambodian ខ្មែរ
- Croatian Hrvatski
- Czech Český
- English English
- Esperanto Esperanto
- Filipino Filipino
- French Français
- German Deutsch
- Greek Ελληνικά
- Hausa Hausa
- Hebrew עברית
- Hungarian Magyar
- Hindi हिन्दी
- Indonesian Bahasa Indonesia
- Italian Italiano
- Japanese 日本語
- Korean 한국어
- Lao ລາວ
- Malay Bahasa Melayu
- Mongolian Монгол
- Myanmar မြန်မာဘာသာ
- Nepali नेपाली
- Persian فارسی
- Polish Polski
- Portuguese Português
- Pashto پښتو
- Romanian Română
- Russian Русский
- Serbian Српски
- Sinhalese සිංහල
- Spanish Español
- Swahili Kiswahili
- Tamil தமிழ்
- Thai ไทย
- Turkish Türkçe
- Ukrainian Українська
- Urdu اردو
- Vietnamese Tiếng Việt
Copyright © 2024 CGTN.
京ICP备20000184号
互联网新闻信息许可证10120180008
Disinformation report hotline: 010-85061466
AstraZeneca recently announced an investment of $2.5 billion in Beijing to establish the pharmaceutical company's sixth global strategic R&D center, together with major research and manufacturing agreements. The new R&D center in Beijing will be AstraZeneca's second such center in China, following the opening of the first R&D center in Shanghai. In an exclusive interview with CGTN's Tian Wei on the sidelines of the Boao Forum for Asia Annual Conference 2025, AstraZeneca's CEO Pascal Soriot highlighted China's explosive growth in pharmaceutical innovation, making Beijing the company's next major R&D hub. Meanwhile, the team in Shanghai is the leader in global clinical programs, taking China's medical expertise to the world.